Logo image of VSTM

VERASTEM INC (VSTM) Stock Fundamental Analysis

USA - Nasdaq - NASDAQ:VSTM - US92337C2035 - Common Stock

7.87 USD
-0.06 (-0.76%)
Last: 12/24/2025, 8:06:04 PM
7.78 USD
-0.09 (-1.14%)
After Hours: 12/24/2025, 8:06:04 PM
Fundamental Rating

1

VSTM gets a fundamental rating of 1 out of 10. The analysis compared the fundamentals against 530 industry peers in the Biotechnology industry. VSTM has a bad profitability rating. Also its financial health evaluation is rather negative. VSTM is valied quite expensively at the moment, while it does show a decent growth rate.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

VSTM had negative earnings in the past year.
VSTM had a negative operating cash flow in the past year.
In the past 5 years VSTM always reported negative net income.
In the past 5 years VSTM always reported negative operating cash flow.
VSTM Yearly Net Income VS EBIT VS OCF VS FCFVSTM Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -50M -100M

1.2 Ratios

VSTM has a worse Return On Assets (-73.87%) than 63.77% of its industry peers.
Industry RankSector Rank
ROA -73.87%
ROE N/A
ROIC N/A
ROA(3y)-88.21%
ROA(5y)-74.8%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
VSTM Yearly ROA, ROE, ROICVSTM Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -500 -1K -1.5K -2K

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for VSTM so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
VSTM Yearly Profit, Operating, Gross MarginsVSTM Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -1K -2K -3K

More info and screens

2

2. Health

2.1 Basic Checks

VSTM does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for VSTM has been increased compared to 1 year ago.
Compared to 5 years ago, VSTM has more shares outstanding
VSTM has a worse debt/assets ratio than last year.
VSTM Yearly Shares OutstandingVSTM Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M 40M
VSTM Yearly Total Debt VS Total AssetsVSTM Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M 200M 250M

2.2 Solvency

Based on the Altman-Z score of -8.52, we must say that VSTM is in the distress zone and has some risk of bankruptcy.
The Altman-Z score of VSTM (-8.52) is worse than 70.38% of its industry peers.
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Altman-Z -8.52
ROIC/WACCN/A
WACC8.7%
VSTM Yearly LT Debt VS Equity VS FCFVSTM Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 50M -50M 100M -100M

2.3 Liquidity

A Current Ratio of 2.58 indicates that VSTM has no problem at all paying its short term obligations.
VSTM has a Current ratio of 2.58. This is in the lower half of the industry: VSTM underperforms 70.19% of its industry peers.
A Quick Ratio of 2.55 indicates that VSTM has no problem at all paying its short term obligations.
VSTM has a Quick ratio of 2.55. This is in the lower half of the industry: VSTM underperforms 68.49% of its industry peers.
Industry RankSector Rank
Current Ratio 2.58
Quick Ratio 2.55
VSTM Yearly Current Assets VS Current LiabilitesVSTM Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M 200M 250M

More info and screens

4

3. Growth

3.1 Past

VSTM shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -21.00%.
The Revenue for VSTM have been decreasing by -10.55% on average. This is quite bad
EPS 1Y (TTM)-21%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-125%
Revenue 1Y (TTM)N/A
Revenue growth 3Y69.6%
Revenue growth 5Y-10.55%
Sales Q2Q%N/A

3.2 Future

The Earnings Per Share is expected to grow by 18.78% on average over the next years. This is quite good.
VSTM is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 121.35% yearly.
EPS Next Y8.16%
EPS Next 2Y18.78%
EPS Next 3Y15.19%
EPS Next 5Y18.78%
Revenue Next Year210.11%
Revenue Next 2Y239.37%
Revenue Next 3Y185.56%
Revenue Next 5Y121.35%

3.3 Evolution

The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
VSTM Yearly Revenue VS EstimatesVSTM Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 200M 400M 600M
VSTM Yearly EPS VS EstimatesVSTM Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 0 -5 -10 -15 -20 -25

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for VSTM. In the last year negative earnings were reported.
Also next year VSTM is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
VSTM Price Earnings VS Forward Price EarningsVSTM Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
VSTM Per share dataVSTM EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -1 -2 -3

4.3 Compensation for Growth

VSTM's earnings are expected to grow with 15.19% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y18.78%
EPS Next 3Y15.19%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for VSTM!.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

VERASTEM INC

NASDAQ:VSTM (12/24/2025, 8:06:04 PM)

After market: 7.78 -0.09 (-1.14%)

7.87

-0.06 (-0.76%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-04 2025-11-04/bmo
Earnings (Next)03-18 2026-03-18/amc
Inst Owners77.98%
Inst Owner Change15.03%
Ins Owners0.42%
Ins Owner Change-0.38%
Market Cap607.17M
Revenue(TTM)10.00M
Net Income(TTM)-130.64M
Analysts85.33
Price TargetN/A
Short Float %25.31%
Short Ratio7.79
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-29.89%
Min EPS beat(2)-108.2%
Max EPS beat(2)48.42%
EPS beat(4)1
Avg EPS beat(4)-32.54%
Min EPS beat(4)-108.2%
Max EPS beat(4)48.42%
EPS beat(8)3
Avg EPS beat(8)-15.88%
EPS beat(12)6
Avg EPS beat(12)-9.72%
EPS beat(16)8
Avg EPS beat(16)-6.19%
Revenue beat(2)2
Avg Revenue beat(2)90.77%
Min Revenue beat(2)86.8%
Max Revenue beat(2)94.73%
Revenue beat(4)2
Avg Revenue beat(4)-4.62%
Min Revenue beat(4)-100%
Max Revenue beat(4)94.73%
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)3.23%
PT rev (3m)3.23%
EPS NQ rev (1m)2.85%
EPS NQ rev (3m)16.46%
EPS NY rev (1m)-18.47%
EPS NY rev (3m)-18.03%
Revenue NQ rev (1m)1.93%
Revenue NQ rev (3m)40.18%
Revenue NY rev (1m)50.11%
Revenue NY rev (3m)50.19%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 60.72
P/FCF N/A
P/OCF N/A
P/B N/A
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-3.86
EYN/A
EPS(NY)-2.06
Fwd EYN/A
FCF(TTM)-1.83
FCFYN/A
OCF(TTM)-1.72
OCFYN/A
SpS0.13
BVpS-0.2
TBVpS-0.42
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -73.87%
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-88.21%
ROA(5y)-74.8%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score2
Asset Turnover0.06
Health
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 1894.51%
Cap/Sales 82.79%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 2.58
Quick Ratio 2.55
Altman-Z -8.52
F-Score2
WACC8.7%
ROIC/WACCN/A
Cap/Depr(3y)35.9%
Cap/Depr(5y)41.04%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-21%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-125%
EPS Next Y8.16%
EPS Next 2Y18.78%
EPS Next 3Y15.19%
EPS Next 5Y18.78%
Revenue 1Y (TTM)N/A
Revenue growth 3Y69.6%
Revenue growth 5Y-10.55%
Sales Q2Q%N/A
Revenue Next Year210.11%
Revenue Next 2Y239.37%
Revenue Next 3Y185.56%
Revenue Next 5Y121.35%
EBIT growth 1Y-24.84%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5Y36.99%
FCF growth 1Y-92.03%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-80.75%
OCF growth 3YN/A
OCF growth 5YN/A

VERASTEM INC / VSTM FAQ

Can you provide the ChartMill fundamental rating for VERASTEM INC?

ChartMill assigns a fundamental rating of 1 / 10 to VSTM.


What is the valuation status of VERASTEM INC (VSTM) stock?

ChartMill assigns a valuation rating of 0 / 10 to VERASTEM INC (VSTM). This can be considered as Overvalued.


What is the profitability of VSTM stock?

VERASTEM INC (VSTM) has a profitability rating of 0 / 10.